Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion–positive solid tumors.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Vivek Subbiah, Mimi I-Nan Hu, Justin F. Gainor, Aaron Scott Mansfield, Guzman Alonso, Matthew H. Taylor, Viola Weijia Zhu, Pilar Garrido, Alessio Amatu, Robert C Doebele, Philippe Cassier, Bhumsuk Keam, Martin H. Schuler, Hui Zhang, Corinne Clifford, Michael Palmer, Jennifer Green, Christopher D. Turner, Giuseppe Curigliano
Institutions: The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Mayo Clinic, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of California, Irvine, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University of Colorado Cancer Center, Centre Léon Bérard, Seoul National University Hospital, Essen University Hospital, Blueprint Medicines (United States), University of Milan, European Institute of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3031954810